Per the announcement, Hims & Hers will no longer advertise its compounded semaglutide options on its platform or in its marketing, and will provide patients using the compounded products with an opportunity to transition to FDA-approved products
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
For those seeking quick answers and convenience, AI-powered tools plus clinician video visits can speed evaluation without compromising safety
Early intervention is generally associated with better outcomes, and clinicians should not attribute new joint symptoms solely to pre-existing conditions without appropriate reassessment
While one might think adding a GLP-1 agonist would help, the primary effect of high-dose agonists is usually a further slowing of the upper GI tract
Incretin-based agents are also not expected to cause clinically significant cytochrome P450 (CYP)-mediated pharmacokinetic interactions, meaning the metabolism of testosterone is unlikely to be directly affected
.webp)
